2-甲基-2-丙基-2,6-二氮杂螺[3.5]壬烷-6-羧酸酯 | 939793-21-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂螺癸烷衍生物
• 中文名称: 2-甲基-2-丙基-2,6-二氮杂螺[3.5]壬烷-6-羧酸酯
• 中文别名: 1,7-二氮杂螺[4.5]癸烷-7-羧酸1,1-二甲基乙酯；7-BOC-1,7-二氮杂-[4.5]癸烷
• 英文名称: tert-butyl 1,7-diazaspiro[4.5]decane-7-carboxylate
• 英文别名: tert-butyl 1,9-diazaspiro[4.5]decane-9-carboxylate
• CAS: 939793-21-2
• 化学式: C₁₃H₂₄N₂O₂
• mdl: MFCD08752633
• 分子量: 240.346
• InChiKey: PDFULYHFVRJQJO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.923
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  2-甲基-2-丙基-2,6-二氮杂螺[3.5]壬烷-6-羧酸酯 、 (E)-3-(6-(cyclopropylcarbamoyl)-7-hydroxy-4-isobutyl-2-methyl-5-oxo-4,5-dihydropyrazolo[1,5-a]pyrimidin-3-yl)acrylic acid 在 4-二甲氨基吡啶 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 以95.6 mg的产率得到tert-butyl (E)-1-(3-(6-(cyclopropylcarbamoyl)-7-hydroxy-4-isobutyl-2-methyl-5-oxo-4,5-dihydropyrazolo[1,5-a]pyrimidin-3-yl)acryloyl)-1,7-diazaspiro[4.5]decane-7-carboxylate
  参考文献：
  名称：

  EP4219500

  摘要：

  公开号：

文献信息

• FUSED HETEROCYCLIC COMPOUNDS AS CAM KINASE INHIBITORS
  申请人：Gilead Sciences, Inc.

  公开号：US20180148457A1

  公开（公告）日：2018-05-31

  The present disclosure relates to compounds that are CaM Kinase inhibitors and to their use in the treatment of various disease states, including atrial fibrillation and myocardial infarction. In particular embodiments, the general structure of the compounds is given by Formula I: wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 9 and R 10 are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.

  本公开涉及的化合物是CaM激酶抑制剂，用于治疗各种疾病状态，包括心房颤动和心肌梗死。在特定实施例中，化合物的一般结构由公式I给出：其中R1、R2、R3、R4、R5、R6、R9和R10如本文所述，涉及化合物的制备和使用方法以及含有相同化合物的药物组合物。
• Fused heterocyclic compounds as CaM kinase inhibitors
  申请人：Gilead Sciences, Inc.

  公开号：US10100058B2

  公开（公告）日：2018-10-16

  The present disclosure relates to compounds that are CaM Kinase inhibitors and to their use in the treatment of various disease states, including atrial fibrillation and myocardial infarction. In particular embodiments, the general structure of the compounds is given by Formula I: wherein R1, R2, R3, R4, R5, R6, R9 and R10 are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.

  本公开涉及作为 CaM 激酶抑制剂的化合物及其在治疗包括心房颤动和心肌梗塞在内的各种疾病状态中的用途。在特定的实施方案中，化合物的一般结构由式 I 给出： 其中 R1、R2、R3、R4、R5、R6、R9 和 R10 如本文所述。
• Substituted nucleoside analogues for use as PRMT5 inhibitors
  申请人：Janssen Pharmaceutica NV

  公开号：US10898504B2

  公开（公告）日：2021-01-26

  The present invention relates novel substituted nucleoside analogues of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PRMT5 inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.

  本发明涉及式 (I) 的新型取代核苷类似物 其中的变量具有权利要求中定义的含义。根据本发明的化合物可用作 PRMT5 抑制剂。本发明还涉及包含所述化合物作为活性成分的药物组合物以及所述化合物作为药物的用途。
• PYRAZOLOPYRIMIDINE DERIVATIVES AS CAM KINASE INHIBITORS
  申请人：Gilead Sciences, Inc.

  公开号：EP3548495B1

  公开（公告）日：2021-01-27
• NOVEL SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS
  申请人：Janssen Pharmaceutica NV

  公开号：US20200289539A1

  公开（公告）日：2020-09-17

  The present invention relates novel substituted nucleoside analogues of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PRMT5 inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.